An optimized decapeptide derived from zebrafish AP2M1A (AP10RW) showed robust antimicrobial activity with enhanced stability through targeted amino acid modifications.
Fish-to-drugA zebrafish immune protein yielded an optimized antimicrobial peptide with enhanced stability for potential therapeutic development
What the researchers found
AP10RW, an optimized decapeptide from zebrafish AP2M1A, demonstrated robust antimicrobial activity with enhanced stability through targeted amino acid modifications.
Why it matters
Zebrafish are a model organism whose immune peptides are increasingly recognized as drug leads. Optimization demonstrates these peptides can be engineered for therapeutic use.
How the study worked
Rational peptide optimization from zebrafish AP2M1A, stability testing, antimicrobial activity assays.
What this study cannot tell us
In vitro characterization. In vivo efficacy and toxicity not assessed. Limited to antibacterial testing.
How to read the evidence
Rational optimization study with activity validation. Early-stage drug development.
When this study was published
Published in 2025.
The bigger picture
Aquatic organisms represent an underexplored source of antimicrobial peptides, and zebrafish offer the advantage of well-characterized genomics for rational peptide design.
Questions still open
- Could AP10RW be effective in animal infection models?
- What is the mechanism of antimicrobial action?
- Would further optimization improve potency and spectrum?
Common questions
Can fish peptides become antibiotics?
Why zebrafish?
Read the original research
Optimized Zebrafish AP2M1A-Derived Decapeptide AP10RW with Robust Stability Suppresses Multidrug-Resistant Bacteria.
Biomolecules, 16(2)
Citation
Gong, Yi; Li, Jun; Zhang, Yameng; Zhang, Xiaozheng; Xie, Jun. (2026). Optimized Zebrafish AP2M1A-Derived Decapeptide AP10RW with Robust Stability Suppresses Multidrug-Resistant Bacteria.. Biomolecules, 16(2). https://doi.org/10.3390/biom16020207